Glamour

Glamour Biotech is a clinical-stage biotechnology company based in Suzhou, China, specializing in the development of mRNA-based vaccines and therapeutics. The company leverages its proprietary mRNA platform and lipid nanoparticle (LNP) delivery technology to target infectious diseases and oncology. Its lead programs include a next-generation COVID-19 vaccine and a shingles vaccine candidate, both designed to offer improved safety and efficacy profiles. Glamour Biotech has established integrated capabilities spanning R&D, clinical development, and large-scale mRNA manufacturing. The company is backed by prominent venture capital firms and aims to address significant unmet medical needs through its versatile nucleic acid technology.